| Patient | Ida B. Wells |
|---|---|
| Date of birth | 1957-07-16 |
| Identifiers | MRN HR-ET022-SYN; SSN (made up) 000-22-5903 |
| Document date | 2026-01-20 |
| Author | Cordelia Ashworth-Banks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of home blood pressure readings, the repeat urine test and the kidney ultrasound, with the nephrology consultation. [S]
Mrs. Wells returns two weeks after her first visit with her home blood pressure log and the outside report she obtained: two years ago another clinic measured her creatinine at 1.05 mg/dL and reported an eGFR of 64 as normal. That report used an older equation that raised the estimate for Black patients; recalculated with the race-free CKD-EPI 2021 equation it is 59, already reduced, and no urine albumin test was done then. Her home readings over seven days average 150/88. She stopped naproxen at the first visit and uses acetaminophen for her knees, which works. Her ankles still swell a little by evening and she is still tired in the afternoons. She had her kidney ultrasound this morning and saw Dr. Lindqvist-Moore of nephrology afterwards. She asked to see each calculation and was given copies. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 150/88 over seven days |
| Earlier result | Creatinine 1.05 two years ago, reported with a race-adjusted eGFR of 64; race-free eGFR 59 |
| Naproxen | Stopped; acetaminophen instead |
| Symptoms | Tiredness and evening ankle swelling, unchanged |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; no fever or weight loss |
| Cardiovascular | Positive | Mild ankle swelling by evening; no chest pain or breathlessness lying flat |
| Genitourinary | Negative | No blood in the urine, foamy urine, or burning |
| Musculoskeletal | Positive | Knee aching, controlled with acetaminophen |
| Integumentary | Negative | No rash or itching |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen | One or two tablets up to three times a day as needed | Oral route | 2026-01-05 | active | S |
| Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-20 | Body height | 157 | cm | S |
| 2026-01-20 | Body weight | 70 | kg | S |
| 2026-01-20 | Body mass index (BMI) [Ratio] | 28.4 | kg/m2 | S |
| 2026-01-20 | Systolic blood pressure | 154 | mm[Hg] | S |
| 2026-01-20 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-01-20 | Heart rate | 76 | /min | S |
| 2026-01-20 | Respiratory rate | 16 | /min | S |
| 2026-01-20 | Body temperature | 36.7 | Cel | S |
| 2026-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-20 | Albumin/Creatinine [Mass Ratio] in Urine | 228 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
Vital signs recorded on 2026-01-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 154/90 (average of two), pulse 76; weight 70.0 kg |
| Cardiovascular | Regular rhythm; no murmur or rub; trace ankle swelling |
| Respiratory | Clear |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established | resolved | confirmed | R94.4 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney disease | active | confirmed | I12.9 | S — Synthetic modern diagnosis; no blood pressure from her life is recorded. |
| Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7% | active | confirmed | N18.32 | S — Synthetic modern diagnosis linked to the kidney disease recorded at her death. |
| Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tiredness | active | confirmed | D63.1 | S — Synthetic laboratory finding. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normal | active | confirmed | E55.9 | S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated cuff, average of two readings) | Every visit | Completed today | 154/90 |
| Self-management | Home blood pressure readings | Seven days to confirm; then the week before each visit while medicines change | Completed today | Seven-day average 150/88 confirms hypertension |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2 | Completed today | 228 mg/g, confirming the intake result of 240 (A2) |
| Laboratory | Creatinine with cystatin C (eGFRcr-cys) | When decisions depend on accuracy, as at diagnosis and referral | Up to date | Done at intake: eGFR 40 by creatinine, 38 with cystatin C; both race-free |
| Laboratory | Urinalysis with microscopy | At diagnosis and with any change | Up to date | Intake sample: 1+ protein, no blood, bland sediment |
| Imaging | Kidney ultrasound | Once, at diagnosis of chronic kidney disease of uncertain cause | Completed today | Small echogenic kidneys; no obstruction or stones |
| Laboratory | Monoclonal protein screen and hepatitis B, hepatitis C and HIV tests | Once, for chronic kidney disease of uncertain cause in an older adult | Up to date | Drawn at intake: no monoclonal protein, normal free light chain ratio; hepatitis B surface antigen, hepatitis C antibody and HIV negative; not immune to hepatitis B |
| Survey | Kidney failure risk equation, 2- and 5-year | At diagnosis and yearly at G3 to G5; before referral decisions | Completed today | About 7% at 5 years and 2% at 2 years (eGFR 38, albumin-to-creatinine ratio 240 mg/g, age 68, female) |
| Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Two to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2) | Ordered | Losartan started today; check in two weeks |
| Laboratory | Hemoglobin | At least yearly at G3; recheck in three months when mildly low | Up to date | 11.2 g/dL at intake; iron studies adequate |
| Laboratory | Calcium, phosphate, intact PTH and 25-hydroxyvitamin D | Baseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacement | Up to date | At intake: calcium 9.2, phosphate 3.8 mg/dL; PTH 84 pg/mL; vitamin D 17 ng/mL; vitamin D3 started today |
| Laboratory | Lipid panel | Once at diagnosis; statin for adults 50 or older with eGFR below 60 without routine repeat testing | Up to date | LDL 136 mg/dL at intake; atorvastatin 20 mg started today, without a routine repeat |
| Medication safety | Medication review: NSAIDs, contrast, dose adjustment, sick-day rules | Every visit | Completed today | Naproxen stopped and acetaminophen used instead; sick-day rules for losartan explained in writing |
| Self-management | Lifestyle: sodium below 2 g a day, activity, plant-rich diet | Every visit | Completed today | Dietitian session booked; sodium and protein targets discussed |
| Medication safety | Vaccines for kidney disease (influenza, pneumococcal, hepatitis B, COVID-19) | Review yearly; hepatitis B series if not immune | Completed today | High-dose influenza, PCV20 and hepatitis B dose 1 given after she agreed |
| Referral | Nephrology | When 5-year kidney failure risk is 3 to 5% or more, eGFR falls quickly, or the cause is unclear | Completed today | Seen by Dr. Lindqvist-Moore today; review in three months |
Goal progress:
Immunizations given today: High-dose influenza vaccine, this season; Pneumococcal conjugate vaccine PCV20; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Potassium and creatinine in two weeks. Kidney education session and dietitian session in the next month. Call for dizziness, swelling of the lips or tongue (call 911), or vomiting or diarrhea that stops her eating and drinking (hold losartan that day). Next scheduled visit 2026-02-03: two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozin. [S]